Alnylam Pharmaceuticals (ALNY) vs Insmed (INSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Insmed (INSM) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, losing 38.8% versus a loss of 49.1%. Over five years, INSM leads with a +279.8% price change compared with +11.6% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($31.13 billion vs $21.97 billion), about 1.4 times the size, while Insmed is growing revenue faster (+66.7% vs +65.2%).
On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (18.7x vs 127.8x for Insmed). Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | INSM |
|---|---|---|
| Share price | $232.68 | $100.60 |
| Market cap | $31.13B | $21.97B |
| 1-day change | +3.63% | +0.12% |
| YTD return | -41.49% | -42.20% |
| 1-year return | -49.08% | -38.81% |
| 5-year return | +11.57% | +279.77% |
| P/E ratio (TTM) | 39.24 | — |
| Forward P/E | 18.73 | 127.76 |
| EPS (TTM) | $5.93 | $-4.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $606.42M |
| Revenue growth (YoY) | +65.19% | +66.73% |
| Net income (latest FY) | $313.75M | $-1.28B |
| Gross margin | 81.77% | 79.73% |
| Operating margin | 13.51% | -205.59% |
| Net margin | 8.45% | -210.54% |
| 52-week high | $495.55 | $212.75 |
| 52-week low | $197.81 | $90.39 |
| Distance from 52-week high | -53.05% | -52.71% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +59.50% | +96.56% |
| Average volume | 1.77M | 2.60M |
| Shares outstanding | 133.81M | 218.38M |
| Employees | 2,500 | 1,664 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INSM has outperformed ALNY by 10.3 percentage points over the past year.
- Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
ALNY vs INSM FAQ
Which is bigger, Alnylam Pharmaceuticals or Insmed?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $31.13B compared with $21.97B for Insmed (INSM).
Which stock has performed better over the past year, ALNY or INSM?
INSM returned -38.81% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and Insmed in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.